Livzon Pharmaceutical Group Revenue and Competitors

丽珠医药集团股份有限公司是集医药研发、生产、销售为一体的综合性企业集团，创建于1985年1月，注册资本为4.25亿元。集团现拥有18个专利产品，21个独家产品，其中参芪扶正注射液和艾普拉唑先后荣获广东省科技进步一等奖。2016年1月，集团原研新药艾普拉唑又荣获国家科技进步二等奖殊荣。 近几年来，公司先后获得国内多个行业荣誉：2011年被评为中国最具竞争力医药上市公司20强，2012年被评为最佳上市企业治理10强；2013年被评为上市企业投资价值TOP10强，2014-2015年被评为中国最具品牌价值500强企业。 丽珠系中国医药50强、国家技术创新示范企业。2014年完成了B转H股，系行业第一家。2016年，集团将整体搬迁至金湾区丽珠工业园，丽珠工业园占地42.7万平方米，总投资约20亿元人民币，是按美国FDA和欧盟标准建造的国际一流的现代化制药生产基地。 公司永远致力于人类健康事业，提供国内领先、国际一流的特色专科药，公司正致力于向生物制药的战略转型，开拓布局“精准医疗”领域!根据公司发展战略，到2017年将实现销售目标100亿的目标。 Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products. Livzon has 9 GMP production plants located in Guangdong, Shanghai, Sichuan, Fujian, 3 plantation bases for Chinese drug preparation production located in Shanxi, Gansu, Yunan of China, with more than 5,700 employees. Livzon has modern industrial chain and product group, operates to manufacture drug preparation, bulk medicines and intermediates, as well as diagnostic reagents and equipment, with approximate 280 products therapeutically grouped as gastrointestinal, cardio-cerebral-vascular, anti-biotic, gonadotropic hormone etc. Meanwhile, Livzon possesses production bases as leading manufacturer of Chinese drug preparation injection, and specialist bulk medicines and intermediates such as fermented antibiotics, sterile cephalosporins, and hypolipidemic “statins”. All production lines are compliant with GMP requirements, including some DMFs, USA FDA inspection and COS approvals etc. Benefited from the regulatory compliance, an extensive overseas market is under robust development, including India, Japan, Eastern Europe for bulk medicines and intermediates, and the Philippines, Kyrgyzstan, Uzbekistan, Tajikistan, Hong Kong and Pakistan for drug preparation. In recent years, Livzon implement the strategic transformation of R&D, focusing to antibody medicines and vaccines, and it has already established laboratories of antibody medicines and vaccine development. At the meanwhile, Livzon adjusts R&D direction of chemical pharmaceutical for carrying out transformation and upgrade. Livzon forms a complete research system. In addition, Livzon has established long-term cooperative relationship with more than 30 domestic and overseas scientific research institutes.